Table 3.

Unanswered questions in the treatment of advanced epithelial ovarian cancer

Can we identify better predictors of risk for recurrence or chemoresistance?

Can we identify individual variation in gene expression governing drug metabolism which affect both toxicity and efficacy?

Can we identify genomic patterns which are prognostic or predictive or response to specific drugs or treatment combinations?

Which patients are best served by neoadjuvant chemotherapy followed by interval cytoreduction?

How can we best use targeted biologics in combination with initial chemotherapy to improve outcome?

How can we reduce the toxicity and improve the efficacy of intraperitoneal chemotherapy?

Does the use of dose-dense (weekly) paclitaxel obviate the benefit of intraperitoneal chemotherapy?

Should we administer both carboplatin and paclitaxel weekly?

Does the use of targeted biologics obviate the benefit of intraperitoneal chemotherapy?

Should consolidation therapy be offered to all patients after initial treatment with debulking surgery and chemotherapy?